Navigation Links
Rosetta Genomics Reports First Quarter 2008 Financial Results
Date:5/21/2008

ntiate squamous from non squamous non-small cell lung cancer (NSCLC) and is the first of three tests the company expects will be submitted for regulatory approval by CLIA certified labs in 2008.

In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta's proprietary microRNA technology.

On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.

Financial Overview

Operating loss for the first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.

Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company's largest expense and accounted for 64% of its operating losses.

As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.

As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two a
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Apache Junction, AZ (PRWEB) June 02, 2015 ... of light microscope technology, Yancy Corporation is ... with any desired material and biological sample, displaying the ... and electron bonds between atoms. , Jeff Porter, Co-Founder ... new physics are just that – rare. They come ...
(Date:6/1/2015)... New York, NY (PRWEB) June 02, 2015 ... informative views on health care, Jack Uldrich has ... pharmaceutical firm in New York today. He will ... , Uldrich has delivered presentations to ... American Academies of Audiology and Neurology, Alcetel-Lucent/Verizon Forum ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
(Date:6/1/2015)... N.J. , June 1, 2015  Novartis ... clinical study of CTL019, an investigational chimeric antigen ... potential in the treatment of specific types of ... conducted by the University of Pennsylvania,s Perelman School ... refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... PARIS, September 30 , ... Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... today results of a,head-to-head study providing further evidence on the ... compared,to twice-daily insulin detemir. The study was presented during the ...
... Mass., Sept. 29 Dr. John McPherson, Platform Leader, ... Project Manager, of the Ontario Institute for Cancer Research ... a thorough evaluation of the NEBNext(TM) DNA Sample Prep ... Dr. McPherson said of the evaluation, "We are constantly ...
... Michigan physicists have created the first atomic-scale maps ... goal of producing "designer dots" that can be ... artificial atoms or nanoparticles---are tiny semiconductor crystals with ... devices and other technologies. Each dot is a ...
Cached Biology Technology:Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2U-M physicists create first atomic-scale map of quantum dots 2
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2
... Waimanalo, HI ?December 12, 2006 -- A new study in ... shrimp consistently win over smaller shrimp of the same gender ... female shrimp ?even though adult males of the species are ... age. , "Both size and gender are important factors in ...
... population peaks on the edges of the gypsy moth range ... to a team of researchers. , "Slowing the spread of ... the U.S.," says Ottar Bjornstad, associate professor of entomology and ... spread of invasive species is important for successful management." ...
... University of Leicester scientists are heading a worldwide research ... diarrhoea in children in developing countries. , The four-year ... in four hospitals in India, will offer a means ... disease quickly, cheaply and with little training necessary for ...
Cached Biology News:Edge density key to controlling gypsy moth spread 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3
... Express Cloning Checker Kits provide two highly ... transformation without time-consuming plasmid preparation. By using ... all you need to do is to ... directly from the transformation plates into the ...
Recombinant Equine IL-4, CF...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
delta-like 1 homolog (Drosophila)...
Biology Products: